Could this be another Greencross
Could this be another Greencross? The size of the opportunity in the companion animal market is dangerous to underestimate. Those that passed up Greencross may have noticed they missed a 1600% gain over the last five years. But very few new stories in this niche come through. Next in line is Nexvet which is unlisted. Morgans is doing a pre-IPO round now, and plans to IPO it later in CY014. They have a suite of monoclonal antibodies which will compete with the tired old conventional pharmaceuticals. As a former Vet myself, the product appeal is obvious to me. Stateside the sector is riding the biotech wave, with Nexvet's Nasdaq peers jumping on IPO to then increase in multiples.